SCN8A Epilepsy clinical trials at UCSF
2 in progress, 1 open to eligible people
SCN8A epilepsy is a rare genetic disorder that causes seizures and developmental delays. UCSF is testing a new drug called NBI-921352 to see if it helps people with SCN8A epilepsy. We are checking if the drug is safe and how it works in the body.
NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
open to eligible people ages 2-21
The objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).
San Francisco, California and other locations
Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE
Sorry, accepting new patients by invitation only
Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).
San Francisco, California and other locations
Last updated: